”SōRSE intends to collaborate with other researchers and product developers to study cannabinoids in other medical applications. Pascal will continue to pursue other non-cancer indications for PAS-393.
“This is an impressive step forward for both Pascal and SōRSE, and hopefully our product will be a significant help to patients,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “This will be the first clinical trial for each company, and we look forward to a long, fruitful relationship.”
About Pascal Biosciences Inc.
Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal’s leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. For more information, visit www.pascalbiosciences.com.
Pascal recently discovered the unique capacity of its cannabinoid drug, PAS-393, to reverse a common immune-evading strategy adopted by many metastatic cancers. Thus, treatment with PAS-393 may restore the ability of the immune system to recognize and eliminate cancer cells. This activity is especially important for immune checkpoint inhibitors, which depend upon immune recognition of cancer for their efficacy. Pascal is advancing PAS-393 as a combination therapy with checkpoint inhibitors for the 50% or more of cancer patients not currently helped by the checkpoint inhibitors.
About SōRSE Technology Corporation
SōRSE Technology Corporation is a water-soluble emulsion technology designed for product developers to provide consumers with a better, more consistent cannabinoid experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Its patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for infusing CBD and other functional ingredients into beverages, food items, topicals, and medical applications. SōRSE Technology currently powers more than 45 leading products in the CBD space.
SōRSE Technology Press:
Jon Lindsay Phillips
Reuters exclusive — On September 14th, SōRSE Technology announced the partnership with Pascal Biosciences Inc. to start an early stage study of a cannabis-based cancer therapy. Learn more about this collaboration.
Check out our partner, Mad Tasty’s feature in Fortune where founder, Ryan Tedder, dives into the lessons he’s learned during his first year operating Mad Tasty and how SōRSE Technology played a key role in the launch of the CBD beverages. Read the full article.
Hear it from our partner, KLEER CBD Water — SōRSE Technology makes it possible for the CBD to remain evenly suspended throughout the can, so that the effect remains equal from the first sip down to the last. Learn more about KLEER CBD Water in their feature in The Beer Connoisseur.
Our partner, KLEER CBD Water, just launched their line of CBD-infused sparkling water, powered by SōRSE!
Learn more about cannabis beverages and how they have finally taken off in this article in Rolling Stone, featuring SōRSE and our partner, Cann.
Through our partnership with The Valens Company and A1 Cannabis, our technology powered the first cannabis beverage to market in Canada!
“These products were developed using the SōRSE by Valens emulsion technology which transforms cannabis oil into water-soluble extracts while eliminating cannabis taste, colour, or smell. These beverages have a fast onset time, significantly reduce offset time, increased bioavailability of cannabinoids, and are stable enough to achieve more than a one-year shelf life.”
Check out the full overview of the current beverage market in Canada from ADCANN.
Edibles are already a staple of many people’s cannabis lineup, and lately, due to the pandemic, some may even be choosing to forgo smoking entirely and switch to edibles due to health concerns.
Read about our CSO, Scott Riefler’s insights on edibles and its shelf life in Leafly’s article.